| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 79, 1322-1327, Copyright © 1994 by Endocrine Society
ARTICLES |
K Ikeda, H Ohno, M Hane, H Yokoi, M Okada, T Honma, A Yamada, Y Tatsumi, T Tanaka and T Saitoh
Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.
We have developed a sensitive immunoradiometric assay for PTH-related peptide (PTHrP) using a monoclonal antibody against PTHrP(1-34) and a polyclonal antibody against PTHrP(50-83), with recombinant human PTHrP(1-87) as the standard. The detection limit of the immunoradiometric assay was 0.5 pmol/L, and plasma PTHrP(1-87) concentrations in 110 healthy subjects were 0.8 +/- 0.01 pmol/L, with the upper limit of the normal range being 1.1 pmol/L. Increased circulating PTHrP(1-87) concentrations were demonstrated in all 46 cancer patients with hypercalcemia, but not in patients with primary hyperparathyroidism, chronic renal failure, or hypoparathyroidism. Normalization of serum calcium levels after resection of tumors was shown to correlate well with that of plasma PTHrP(1-87) concentrations in 2 cancer patients. High circulating PTHrP(1-87) levels were also demonstrated in 12 out of 13 hypercalcemic patients with adult T-cell leukemia/lymphoma and in 7 out of 8 hypercalcemic patients with non- Hodgkin's lymphoma especially of B-cell type. These results suggest that PTHrP is a major humoral factor responsible for the hypercalcemia frequently associated with adult T-cell leukemia/lymphoma and also with B-cell lymphoma.
This article has been cited by other articles:
![]() |
T. Yokote, T. Akioka, S. Hara, S. Oka, H. Miyamoto, T. Yamano, M. Sugino, M. Tsuji, and T. Hanafusa Patients With Malignancy Requiring Urgent Therapy: CASE 2. Bilateral Renal Swelling Induced by Adult T-Cell Leukemia/Lymphoma J. Clin. Oncol., September 20, 2005; 23(27): 6793 - 6794. [Full Text] [PDF] |
||||
![]() |
G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Dumon, T. Jensen, B. Lueddecke, J. Spring, J. Barle, and J.-J. Body Technical and Clinical Validation of an Immunoradiometric Assay for Circulating Parathyroid Hormone-related Protein Clin. Chem., March 1, 2000; 46(3): 416 - 418. [Full Text] [PDF] |
||||
![]() |
T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |